LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position … to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … and we are pleased to partner with them, aiming to bring a therapy to patients in an area of unmet need for a …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNAtherapy in Leber congenital amaurosis 10 (LCA10) Presenter: …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNAtherapy in Leber congenital amaurosis 10 (LCA10) Presenter: …
Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data